MSB 2.91% $1.06 mesoblast limited

GVHD in US

  1. 3,839 Posts.
    lightbulb Created with Sketch. 359

    Just my take on MSB:


    With all the LVAD issues. I'm waiting for news on the pre-BLA meeting. Which was targeted for Q4 CY2018;

    I think the delay may be one FDA and MSB  planning the commercial side of things like pricing and product launch. (Using Temsell Japan as a guide to determine commercial strategy for the US)


    If this gets sorted out the Sp will jump. We are also waiting on the low back pain. News surely will come out within 6 months.


    With the big ticket, 'Heart', end of 2019 or early 2020.


    Bio stocks are risky but MSB is worth the risk.


    With all the selling and negativity. One thing I don't want to hear is a a big fund manager has sold!

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.06
Change
0.030(2.91%)
Mkt cap ! $1.210B
Open High Low Value Volume
$1.05 $1.09 $1.03 $5.796M 5.430M

Buyers (Bids)

No. Vol. Price($)
2 15990 $1.06
 

Sellers (Offers)

Price($) Vol. No.
$1.08 48632 3
View Market Depth
Last trade - 16.10pm 02/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.